Claims
- 1. A subunit vaccine composition comprising a herpes simplex virus (HSV) VP22 polypeptide capable of eliciting a cellular immune response in a mammalian subject, and a pharmaceutically acceptable excipient.
- 2. The composition of claim 1, wherein the VP22 is from HSV type 1 (HSV-1).
- 3. The composition of claim 1, wherein the VP22 is from HSV type 2 (HSV-2).
- 4. The composition of claim 1, further comprising a HSV VP16 polypeptide.
- 5. The composition of claim 4, wherein the VP16 polypeptide is from HSV-1.
- 6. The composition of claim 4, wherein the VP16 polypeptide is from HSV-2.
- 7. The composition of claim 1 further comprising a HSV glycoprotein polypeptide.
- 8. The composition of claim 7, wherein the glycoprotein is a gB polypeptide from HSV-1.
- 9. The composition of claim 7, wherein the glycoprotein is a gB polypeptide from HSV-2.
- 10. The composition of claim 7, wherein the glycoprotein is a gD polypeptide from HSV-1.
- 11. The composition of claim 7, wherein the glycoprotein is a gD polypeptide from HSV-2.
- 12. The composition of claim 1, further comprising an adjuvant.
- 13. A method of producing a composition for the treatment or prevention of herpes simplex virus (HSV) infection comprising:
(a) providing an isolated HSV VP22 polypeptide which is capable of eliciting a cellular immune response in a mammalian subject; and (b) formulating the HSV VP22 polypeptide with a pharmaceutically acceptable excipient.
- 14. The method of claim 13, wherein the VP22 is from HSV type 1 (HSV-1).
- 15. The method of claim 13, wherein the VP22 is from HSV type 2 (HSV-2).
- 16. The method of claim 13, wherein the composition further comprises a HSV VP16 polypeptide.
- 17. The method of claim 16, wherein the VP16 polypeptide is from HSV-1.
- 18. The method of claim 16, wherein the VP16 polypeptide is from HSV-2.
- 19. The method of claim 13, wherein the composition further comprises a HSV glycoprotein polypeptide.
- 20. The method of claim 19, wherein the glycoprotein is a gB polypeptide from HSV-1.
- 21. The method of claim 19, wherein the glycoprotein is a gB polypeptide from HSV-2.
- 22. The method of claim 19, wherein the glycoprotein is a gD polypeptide from HSV-1.
- 23. The method of claim 19, wherein the glycoprotein is a gD polypeptide from HSV-2.
- 24. The method of claim 13, further comprising adding an adjuvant.
- 25. A method for treating or preventing HSV infection in a mammalian subject comprising administering an amount of the composition of claim 1 effective to elicit a cellular immune response, to the subject.
- 26. A method for treating or preventing HSV infection in a mammalian subject comprising administering an amount of the composition of claim 4 effective to elicit a cellular immune response, to the subject.
- 27. A method for treating or preventing HSV infection in a mammalian subject comprising administering an amount of the composition of claim 6 effective to elicit a cellular immune response, to the subject.
- 28. A method for treating or preventing HSV infection in a mammalian subject comprising administering an amount of the composition of claim 12 effective to elicit a cellular immune response, to the subject.
- 29. The method of claim 25, wherein the administering is done prior to primary infection with HSV.
- 30. The method of claim 25, wherein the administering is done subsequent to primary infection with HSV.
- 31. A viral vector comprising a gene encoding a herpes simplex virus (HSV) VP22 polypeptide capable of eliciting a cellular immune response in a mammalian subject.
- 32. The viral vector of claim 31, wherein the gene encoding the VP22 polypeptide is from HSV type 1 (HSV-1).
- 33. The viral vector of claim 31, wherein the gene encoding the VP22 polypeptide is from HSV type 2 (HSV-2).
- 34. A method for treating or preventing HSV infection in a mammalian subject comprising administering the viral vector of claim 31 to the subject.
- 35. A method for treating or preventing HSV infection in a mammalian subject comprising administering the viral vector of claim 32 to the subject.
- 36. A method for treating or preventing HSV infection in a mammalian subject comprising administering the viral vector of claim 33 to the subject.
- 37. A vaccine composition comprising a recombinant vector which comprises a gene encoding a herpes simplex virus (HSV) VP22 polypeptide operably linked to control elements that direct the transcription and translation of the gene in a mammalian host cell, and a pharmaceutically acceptable excipient.
- 38. The composition of claim 37, wherein the gene encoding the VP22 polypeptide is from HSV type 1 (HSV-1).
- 39. The composition of claim 37, wherein the gene encoding the VP22 polypeptide is from HSV type 2 (HSV-2).
- 40. The composition of claim 37, wherein said recombinant vector is a nonviral vector.
- 41. The composition of claim 37, wherein said recombinant vector is a viral vector.
- 42. The composition of claim 41, wherein said viral vector is a retroviral vector.
- 43. The composition of claim 37, wherein said recombinant vector is derived from a Sindbis virus.
- 44. The composition of claim 37, wherein said recombinant vector is encapsulated in a liposome preparation.
- 45. A method for treating or preventing HSV infection in a mammalian subject comprising administering the composition of claim 37 to the subject.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is related to provisional patent application serial No. 60/047,359, filed Jun. 2, 1997, from which priority is claimed under 35 USC §119(e) (1) and which application is incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60047359 |
Jun 1997 |
US |